Jeff J. Guo, BPharm, PhD, PhD, is a full Professor tenured at the University of
Cincinnati (UC) College of Pharmacy and a Faculty Research Fellow of Department of Public Health
Sciences at the UC College of Medicine. He has been teaching graduate courses, e.g.,
Pharmacoepidemiology & Drug Safety, Clinical Trial Phase III & IV Research & Design, Evidence-based
Pharmacotherapy, Pharmaceutical Economics Policy, and Biostatistics & research methods at UC. He has
served as major advisor for 14 PhD, 32 MS, and numerous PharmD students. Prior to joining UC, he worked
as a drug information specialist/senior pharmacy engineer at the United States Pharmacopeia
(Rockville, Maryland) 1996-1999. He also worked as CRO research manager at the Degge Group Ltd.
(Arlington, Virginia) 1999-2000, and at the China Food & Drug Administration (Beijing, China) 1983-1991.
He has been a Co-Editor for Value-in-Health Regional Issues 2011-2017, and sits on editorial boards of
Research in Social Administrative Pharmacy, Chinese Journal of Pharmacoepidemiolgy, Journal
of Preventive Medicine, Intractable Rare Diseases Research, Health Services & Policy Journal, and
American Health & Drug Benefits. He is a founder and the past Chair for the International
Society for Pharmacoeconomics and Outcomes Research (ISPOR) Asian Consortium Advisory Committee.
He was invited expert panel member for Bill Gates Foundation, Brookings Institute, and invited speaker
at the US FDA, US Census Bureau, University of Chicago, the World Bank, Tokyo University, UC Berkley,
University of Brasilia, Beijing University, etc. He has extensive project experience with Ohio and
Alabama state Medicaid rational drug utilization reviews and health policy research, the U.S.
Pharmacopeia Drug Information, and the U.S. national medication error report system (MedMARx®).
He has had contract research experience with the U.S. government, health foundation, and several
major pharmaceutical companies such as Bristol-Myers Squibb, Genentech, Baxter, Novartis, and
Johnson & Johnson.
He published several textbook chapters in pharmaceutical policy and pharmacoepidemiology, as well as
over 140 peer-reviewed research papers in different journals including JAMA, Lancet, British Medical
Journal, Annals of Internal Medicine, Pharmacoepidemiology Drug Safety, Journal of Clinical Psychiatry,
Public Health Reports, Stroke, Pharmacotherapy, Pharmacoeconomics, Value in Health and Annals of
Pharmacotherapy. His major research topics involve following areas: real world evidence, drug safety
and pharmacovigilance, drug-induced adverse toxicity, drug utilization, health insurance policy,
physician prescribing behavior, drug price, drug information, Phase IV clinical research, drug development
regulatory, pharmaceutical market competition, rare disease and orphan drugs, cost-benefit analysis
for medications, the risk-benefit measurement, drug policy, as well as health outcomes research.
Dan Greenberg is an Associate Professor and Chairman of the Department of Health Systems Management at the Faculty of Health Sciences and the Guilford-Glaser Faculty of Business and Management at Ben-Gurion University of the Negev in Israel, where he teaches on comparative healthcare systems, health technology assessment, and economic evaluation of technologies in healthcare. Since 2008, he is also affiliated with the Center for the Evaluation of Value and Risk in Health (CEVR) at The Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, Boston, MA, and is an adjunct faculty at the Tufts University School of Medicine.
Dan is a co-founder and the former President of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel), and is currently co-editor of
Value in Health and member of the editorial board of Applied Health Economics and Health Policy. Dr. Greenberg received his doctorate degree fro
Ben-Gurion University of the Negev in 2001.
After receiving his doctorate degree from Ben-Gurion University of the Negev in 2001, Dr. Greenberg completed a 3-year post-doctoral research fellowship at the Harvard Clinical Research Institute & Cardiovascular Division, Beth Israel Deaconess Medical Center, and Harvard Medical School, initially as a Fulbright Scholar. He was also a Visiting Scientist at the Department of Health Policy and Management at the Harvard School of Public Health. His research focuses on economic evaluation of healthcare technologies, health technology policy, medical decision-making and outcomes research. He has conducted economic evaluations for various medical interventions and contributed to the literature on the willingness to pay for cardiovascular interventions, diffusion of innovations, and the use of economic evaluations for coverage and reimbursement decisions at the national level. Dr. Greenberg authored or co-authored over 60 papers and book chapters and published his work in leading medical and health policy journals, such as the British Medical Journal, Annals of Internal Medicine, Journal of the National Cancer Institute, Health Affairs, and Value in Health.
J. Jaime Caro, MDCM, FRCPC, FACP, is Chief Scientist at Evidera. Dr. Caro advances Evidera’s leadership in developing and applying novel techniques in modeling, health economics, comparative effectiveness, epidemiology, and outcomes research. Dr. Caro trained at McGill University, where he practiced internal medicine and continues as adjunct Professor of Medicine, as well as of Epidemiology and Biostatistics. He established the graduate-level course in pharmacoeconomics, which he continues to direct, and also lends his teaching ability to other academic institutions such as Thomas Jefferson University School of Population Health and the Massachusetts College of Pharmacy and Health Sciences.
Dr. Caro continues to pioneer new methodologies. Currently, he is working on a unified approach to health economic modeling that renders the distinctions between Markov and discrete event simulation moot. Previously, Dr. Caro adapted an engineering technique – discrete event simulation – to model diseases and their treatment. This innovation has been extended further to simulate the design of clinical trials and other types of studies, something which has been particularly effective in helping design pragmatic
clinical trials. He has also applied the technique to provide comparative effectiveness information in the absence of head-to-head
trials in a new method called Simulated Treatment Comparison. In response to increasingly frequent requests by authorities to provide
data to support the value of new interventions, Dr. Caro has applied simulation techniques to make post-marketing registries more
feasible and efficient – an approach called SAVES. In an effort to provide an alternative to the well-known cost per QALY technique
and avoid many of the latter’s problems, he proposed an innovative approach to the assessment of health technologies, involving the
efficiency frontier. This method was adopted by the German government health technology assessment agency for its economic analyses.
Dr. Caro recently led the Quality Assurance for Modeling Studies Task Force, jointly sponsored by ISPOR, Academy of Managed Care Pharmacy and the National Pharmaceutical Council. It produced a set of tools to help decision makers assess economic models. Previously, he led the ISPOR-SMDM Good Modeling Practices Task Force, endorsed by the Society for Medical Decision Making, to produce the new guidelines for good modeling practices. This has resulted in seven papers covering topics from the design, through the building and populating, to the validation of models. Recently, Dr. Caro has been working on developing a new modeling technique, DICE, tailored to problems in Health Technology Assessment. He has helped the World Bank Institute and the InterAmerican Court for Human Rights address the growing problem of Supreme Courts overriding health care system decisions and ordering them to provide treatments that had been considered unwarranted.